Please use this identifier to cite or link to this item:
Title: A BioDesign approach to obtain high yields of biosimilars by anti-apoptotic cell engineering: A case study to increase the production yield of anti-TNF alpha producing recombinant CHO cells
Authors: Gülce İz, Sultan
Anıl İnevi, Müge
Sağlam Metiner, Pelin
Ayyıldız Tamiş, Duygu
Kisbet, Nazlı
Keywords: Cell engineering
Chinese hamster ovary cells
Polyethylenimine (PEI)
Transient gene expression (TGE)
Publisher: Humana Press
Source: Gülce İz, S., Anıl İnevi, M., Sağlam Metiner, P., Ayyıldız Tamiş, D., and Kisbet, N. (2018). A BioDesign approach to obtain high yields of biosimilars by anti-apoptotic cell engineering: A case study to increase the production yield of anti-TNF alpha producing recombinant CHO cells. Applied Biochemistry and Biotechnology, 184(1), 303-322. doi:10.1007/s12010-017-2540-2
Abstract: Recent developments in medical biotechnology have facilitated to enhance the production of monoclonal antibodies (mAbs) and recombinant proteins in mammalian cells. Human mAbs for clinical applications have focused on three areas, particularly cancer, immunological disorders, and infectious diseases. Tumor necrosis factor alpha (TNF-α), which has both proinflammatory and immunoregulatory functions, is an important target in biopharmaceutical industry. In this study, a humanized anti-TNF-α mAb producing stable CHO cell line which produces a biosimilar of Humira (adalimumab) was used. Adalimumab is a fully human anti-TNF mAb among the top-selling mAb products in recent years as a biosimilar. Products from mammalian cell bioprocesses are a derivative of cell viability and metabolism, which is mainly disrupted by cell death in bioreactors. Thus, different strategies are used to increase the product yield. Suppression of apoptosis, also called anti-apoptotic cell engineering, is the most remarkable strategy to enhance lifetime of cells for a longer production period. In fact, using anti-apoptotic cell engineering as a BioDesign approach was inspired by nature; nature gives prolonged life span to some cells like stem cells, tumor cells, and memory B and T cells, and researchers have been using this strategy for different purposes. In this study, as a biomimicry approach, anti-apoptotic cell engineering was used to increase the anti-TNF-α mAb production from the humanized anti-TNF-α mAb producing stable CHO cell line by Bcl-xL anti-apoptotic protein. It was shown that transient transfection of CHO cells by the Bcl-xL anti-apoptotic protein expressing plasmid prolonged the cell survival rate and protected cells from apoptosis. The transient expression of Bcl-xL using CHO cells enhanced the anti-TNF-α production. The production of anti-TNF-α in CHO cells was increased up to 215 mg/L with an increase of 160% after cells were transfected with Bcl-xL expressing plasmid with polyethylenimine (PEI) reagent at the ratio of 1:6 (DNA:PEI). In conclusion, the anti-apoptotic efficacy of the Bcl-xL expressing plasmid in humanized anti-TNF-α MAb producing stable CHO cells is compatible with curative effect for high efficiency recombinant protein production. Thus, this model can be used for large-scale production of biosimilars through transient Bcl-xL gene expression as a cost-effective method.
ISSN: 0273-2289
Appears in Collections:Bioengineering / Biyomühendislik
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File Description SizeFormat 
6685.pdfMakale5.24 MBAdobe PDFThumbnail
Show full item record

CORE Recommender


checked on Jul 12, 2024


checked on Jul 13, 2024

Page view(s)

checked on Jul 15, 2024


checked on Jul 15, 2024

Google ScholarTM



Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.